Technology | July 23, 2012

FDA Approves Ferring's Prepopik Colonoscopy Prep

July 23, 2012 — The U.S. Food and Drug Administration (FDA) granted Ferring Pharmaceuticals Inc. approval to market Prepopik (sodium picosulfate, magnesium oxide and anhydrous citric acid) for oral solution indicated for cleansing of the colon as a preparation for colonoscopy in adults. Prepopik is a low-volume, orange-flavored, dual acting, stimulant and osmotic laxative.

The FDA approval is based on data from two pivotal Phase III non-inferiority studies in which Prepopik was compared to 2L PEG+E plus 2x 5-mg bisacodyl tablets. In both studies, Prepopik achieved the primary endpoint (successful colon cleansing based on the Aronchick scale), demonstrating non-inferiority to the comparator (Study 1: 84.2% v. 74.4%; Study 2: 83.0% v. 79.7%). Additionally, Prepopik demonstrated statistical superiority in cleansing of the colon versus the comparator.

The most common (>1%) adverse reactions in Study 1 possibly or probably related to Prepopik (n=305) versus the study comparator (n=298) were nausea (2.6% v. 3.7%), headache (1.6% v. 1.7%) and vomiting (1.0% v. 3.4%). The most common (>1%) adverse reactions in Study 2 possibly or probably related to Prepopik (n=296) versus the comparator (n=302) were nausea (3.0% v. 4.3%), headache (2.7% v. 1.7%) and vomiting (1.4% v. 2.0%).

Once commercially available, Prepopik will be the lowest volume active ingredient colon preparation available – with 10 ounces of prep solution.

Colon cancer is the third most common cancer and second leading cause of cancer death in the United States. Colonoscopies have been shown to help reduce the incidence of colon cancer and deaths associated with the disease. Complete visualization of the bowel is needed to conduct a thorough colonoscopy to identify precancerous lesions and diagnose other gastrointestinal disorders. Aversion to bowel prep solutions, including the substantial liquid volume, has been recognized as a key barrier to completion of essential colonoscopy prep regimens.

"Successful bowel prep is critical for gastroenterologists to clearly see any polyps or abnormalities, yet the sheer volume of prep solutions can prevent patients from adequately completing their prep regimens, leading to suboptimal visualization of the colon," said Douglas K. Rex, director of endoscopy at Indiana University Hospital and professor in the division of gastroenterology and hepatology at University of Indiana School of Medicine.

Prepopik is approved with two dosing options. Preferably, it can be given as the American College of Gastroenterology (ACG)-recommended split-dose taken in the evening before and on the morning of the procedure. Recommended by the ACG as the optimal way to prepare for colonoscopy, split-dosing has been shown to improve cleansing quality given its greater proximity to procedure time, and appears to have higher compliance due to better tolerability of the liquid volume. Day-before dosing is an alternative regimen for patients for whom split-dosing is inappropriate, accounting for colonoscopy scheduling, distance traveled and other personal circumstances.

"Ferring has a strong global GI presence and with this approval, we are very pleased to introduce Prepopik as our first gastroenterology product in the United States," said Aaron Graff, president and chief operating officer, Ferring Pharmaceuticals Inc. "Colonoscopy rates are lower than the target set forth by public health initiatives to detect and prevent colorectal cancer. Adults who have avoided getting screened may benefit from this effective regimen with the lowest active ingredient volume of any FDA-approved bowel prep."

For more information: www.prepopik.com

Related Content

Infrared Colitis Screening Blood Test Could Reduce Dependence on Colonoscopy
News | Colonoscopy Systems | August 31, 2017
August 31, 2017 — A fast, simple blood test for ulcerative colitis using infrared spectroscopy could provide a cheape
Insurance Coverage for CT Colonography Increases Likelihood of Screening
News | Colonoscopy Systems | July 12, 2017
People with insurance policies that cover computed tomography (CT) colonography for colorectal cancer screening are...
CT colonography (CTC) allows visualization of the entire colon in one image

CT colonography (CTC) allows visualization of the entire colon in one image. Photo courtesy of Judy Yee, M.D.

Feature | Imaging | July 05, 2017 | By Jeff Zagoudis
Computed tomography colonography (CTC), also known as virtual colonoscopy, offers a noninvasive alternative to...
Technology | Colonoscopy Systems | March 27, 2017
March 27, 2017 — Bracco Diagnostics Inc. announced the launch of its PROTOCO2L TOUCH Colon Insufflator.
CT colonography, patient and provider groups, Congress, screening, H.R. 1298
News | Colonoscopy Systems | March 02, 2017
Major colorectal cancer care advocacy groups and medical societies have released a statement strongly urging Congress...
Affordable Care Act, economic disparities, mammography, colonoscopy, cancer screening
News | Business | February 08, 2017
Out-of-pocket expenditures are thought to be a significant barrier to receiving cancer preventive services, especially...
Check-Cap, C-Scan system, colorectal cancer screening, clinical trial, CE Mark
News | Colonoscopy Systems | January 31, 2017
Check-Cap Ltd. recently announced the enrollment of the first patient in its multi-center study of the C-Scan system in...
News | Colonoscopy Systems | January 26, 2017
Researchers have developed the first sensor capable of objectively identifying inflammatory bowel disease (IBD) and...
Given, Pillcamp, colonoscopy, Angiodysplasias, capsule Endoscopy, LVAD interference

The Given Imaging PillCam Colon system is an example of a capsule endoscopy device the patient swallows to image the gastrointestinal track.

Feature | Endoscopes | January 03, 2017 | Anamika Kumari
The capsule endoscopy systems offer a hands-free and highly accurate imaging modality for healthcare practitioners.
Overlay Init